< Back to previous page
Patent
Immunotherapy Markers
The present invention relates to the identification and use of neutrophil defensin 1, neutrophil defensin 2 and/or neutrophil defensin 3 as markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.
Patent Publication Number: EP3792632
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
URI: link to Espacenet
Technology domains: Analysis of biological materials
Validated for IOF-key: Yes
Attributed to: Associatie Universiteit & Hogescholen Antwerpen